6, 2013

QUEENSBURY,NY-July 22,2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today
announced that it will host a conference call and webcast on Tuesday, August
6, 2013 at 4:30 p.m. ET to discuss its financial results for the second
quarter of 2013 ended June 30, 2013, and provide an update on recent corporate

The dial-in numbers for the conference call are 866-804-6922 (U.S.
participants) and 857-350-1668 (international participants); both numbers
require passcode 85959025. To access the live webcast, go to the Events &
Presentations page on the Investor Relations section of the Company's website

A taped replay of the call will be available beginning approximately two hours
after the call's conclusion and will be available for seven days. Dial-in
numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and
International callers, respectively. The replay passcode for both U.S. and
International callers is 21059318. An archived webcast will also be available


Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose
chemotherapy and other therapeutic agents to diseased organs or regions of the
body, while controlling the systemic exposure of those agents. The Company's
initial focus is on the treatment of primary and metastatic liver cancers. In
2010, Delcath announced that its randomized Phase 3 clinical trial for
patients with metastatic melanoma in the liver had successfully achieved the
study's primary endpoint of extended hepatic progression-free survival. The
Company also completed a multi-arm Phase 2 trial to treat other liver cancers.
Outside of the United States, our proprietary product to deliver and filter
melphalan hydrochloride is marketed under the trade name Delcath Hepatic
CHEMOSAT® Delivery System for melphalan hydrochloride. The Company obtained
authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery
System for Melphalan in April 2012. The right to affix the CE mark allows the
Company to market and sell the CHEMOSAT Delivery System for Melphalan in
Europe. The Company has not yet received FDA approval for commercial sale of
its system in the United States. The Company's NDA has been accepted for
filing and substantive review by the FDA. For more information, please visit
the Company's website at 

Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the impact of the negative advisory
vote by the ODAC panel on the FDA's decision regarding the Company's new drug
application (NDA), timing of completion of the FDA's review of our NDA, the
extent to which the FDA may request additional information, data, or new
clinical trials and our ability to provide the same in a timely manner,
additional extensions to the PDUFA date by the FDA, acceptability of the Phase
1, 2 and 3 clinical trial data by the FDA, FDA approval of the Company's NDA
for the treatment of ocular metastatic melanoma to the liver, adoption, use
and resulting sales, if any, in the United States, adoption, use and resulting
sales, if any, for the CHEMOSAT system to deliver and filter melphalan in the
EEA, our ability to successfully commercialize the chemosaturation system and
the potential of the chemosaturation system as a treatment for patients with
primary and metastatic disease in the liver, market acceptance of the Gen Two
CHEMOSAT system and patient outcomes using the same, approval of the current
or future chemosaturation system for delivery and filtration of melphalan,
doxorubicin or other chemotherapeutic agents for various indications in the US
and/or in foreign markets, actions by the FDA or other foreign regulatory
agencies, our ability to successfully enter into strategic partnership and
distribution arrangements in foreign markets including Australia and key Asian
markets and timing and revenue, if any, of the same, the approval of the
Hepatic CHEMOSAT Delivery System device to deliver and filter doxorubicin in
key Asian markets and patient outcomes using the same, our ability to obtain
reimbursement for the CHEMOSAT system, uncertainties relating to the timing
and results of research and development projects, uncertainties relating to
the timing and results of future clinical trials, and uncertainties regarding
our ability to obtain financial and other resources for any research,
development and commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and Exchange
Commission. You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We undertake no
obligation to publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.

Investor Contact:           Media Contact:
Gregory Gin/Patty Eisenhaur Chris Gale
EVC Group                   EVC Group
646-445-4801/951-316-0577   646-201-5431



This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.